Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand

Arthritis and Rheumatism
Mitsuko R ItoMasato Nose

Abstract

To characterize Fas antigen expression on the cell surface, and to determine the effect of this expression in rheumatic diseases using a newly established gld-congenic MRL strain of mice (MRL/gld), which is defective in its functional Fas ligand (Fas-L). Flow cytometric analyses of lymphoid cells and macrophages were performed using anti-Fas and other cell surface markers. Histopathologic manifestations were examined using immunochemistry and light and electron microscopy. Serum levels of IgG and anti-DNA antibodies were measured by single radial immunodiffusion and enzyme-linked immunosorbent assay, respectively. MRL/gld mice developed systemic lymphadenopathy with an accumulation of Thy1.2+, B220+ and CD4-, CD8- T cells, which both express the Fas antigen. Splenic B cells positive for surface IgM and/or surface IgD, and resident peritoneal macrophages exhibited up-regulated expression of the Fas antigen, at much higher levels than those observed in MRL/MpJ-+/+ (MRL/+) mice. Forms of rheumatic disease were observed in these mice, although not in C3H/HeJ-gld/gld mice. These forms included diffuse glomerulonephritis, granulomatous arteritis, and arthritis, and were associated with the infiltration of mononuclear cells expressing...Continue Reading

References

Nov 1, 1978·The Journal of Experimental Medicine·B S AndrewsF J Dixon
Jan 1, 1991·Annual Review of Immunology·P L Cohen, R A Eisenberg
Jan 1, 1984·The Journal of Experimental Medicine·J B RothsE M Eicher
Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·D AshanyK B Elkon
Dec 1, 1994·European Journal of Immunology·S M MarianiP H Krammer
Feb 2, 1995·Nature·J DheinP H Krammer
Jan 1, 1994·Advances in Immunology·S Nagata
Oct 1, 1995·European Journal of Immunology·K B OnelK B Elkon
Jan 1, 1996·European Journal of Immunology·J WangT Watanabe
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·M AdachiS Nagata

❮ Previous
Next ❯

Citations

Nov 1, 2000·Arthritis Research·P P TakG S Firestein
Apr 21, 2017·Frontiers in Immunology·Akiko YamadaNaozumi Ishimaru
Jul 31, 1998·Veterinary Pathology·J P Sundberg, D Boggess
Jul 30, 2002·Allergy·A N Theofilopoulos, D H Kono
Nov 1, 2006·Arthritis and Rheumatism·Masatake MuraokaMasaki Yasukawa
Mar 14, 2009·The Tohoku Journal of Experimental Medicine·Yoshiko SogaMasato Nose
Jan 1, 2009·The Journal of Medical Investigation : JMI·Yoshio HayashiNaozumi Ishimaru
Dec 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gil MorFortune Kohen
Jul 30, 2003·Expert Opinion on Therapeutic Targets·Olivier Micheau
Jul 3, 2002·Nature Reviews. Immunology·Richard M Pope
Sep 15, 2005·Rheumatology·S L Peng
Jan 6, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Hiroshi FurukawaMasao Ono
Oct 4, 2000·International Reviews of Immunology·D H Kono, A N Theofilopoulos
Feb 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Saoussen KarrayMatthieu Lévi-Strauss
Aug 14, 2001·European Journal of Immunology·H PerlmanR M Pope
Aug 24, 2016·Nature Reviews. Rheumatology·Carla M CudaHarris Perlman
Apr 27, 2007·Allergology International : Official Journal of the Japanese Society of Allergology·Masato Nose
Aug 18, 2004·Current Opinion in Rheumatology·Yoshio HayashiNaozumi Ishimaru
Dec 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nathaniel J BrownHarris Perlman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis